Drug Profile
ChAdOx1 MVA 5T4 vaccine - Barinthus Biotherapeutics
Alternative Names: ChAdOx1-MVA 5T4; ChAdOx1.5T4; Prostate cancer vaccine - Barinthus Biotherapeutics; VTP-800Latest Information Update: 12 Dec 2023
Price :
$50
*
At a glance
- Originator Vaccitech
- Developer Barinthus Biotherapeutics; University of Oxford
- Class Cancer vaccines; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Prostate cancer
Most Recent Events
- 25 Jul 2022 Phase-II clinical trials in Prostate cancer in United Kingdom (Parenteral) before May 2019 (Vaccitech pipeline, July 2022)
- 25 Jul 2022 Phase-II clinical trials is ongoing in Prostate cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in United Kingdom (Parenteral) before May 2019 (Vaccitech pipeline, July 2022)
- 12 Nov 2021 Vaccitech plans a phase I/IIa trial for Prostate cancer (Combination therapy) in the second quarter of 2022